Evaluation of the Suitability of Selecting a Faecal Microbiota Transplant: Bacterial Composition and Subsequent Long-Term Monitoring of the Viability of Its Frozen and Lyophilised Forms
Source abstract
Abstract
Objectives: The aim of this study was to confirm the effectiveness of FMT on the basis of optimum composition of the faecal microbiota of the donor for support therapy in patients with ulcerative colitis, and to observe the viability of the microbiota in frozen and lyophilised administration forms of FMT under various storage conditions. Methods: The bacterial microbiota composition of the FMT samples was assessed using amplicon sequencing via next-generation sequencing (NGS) technology, conducted on the Illumina MiSeq platform. The BD FACS Canto flow cytometer was used to analyse the metabolic activity of FMT samples. Results: FMT analysis confirmed the presence of key butyrate-producing organisms, specifically highlighting species such as Bifidobacterium adolescentis, Faecalibacterium prausnitzi, Coprococcus catus, Eubacterium rectale, alongside contributions from genera Roseburia and Blautia. These organisms play a crucial role in maintaining intestinal health in humans. The viable microorganism counts were significantly higher (p < 0.001) in the frozen form of FMT (−70 °C) in comparison to lyophilised forms (−70 °C, 4 °C and 20 °C) throughout the storage period. Conclusion: The conducted NGS analyses allowed us to confirm the suitability of our FMT donor as a potential candidate for the target group of patients diagnosed with ulcerative colitis. From the point of view of optimum utilisation of FMT at its highest metabolic activity for the purpose of transplantation, its storage for a maximum of 2 months under specified conditions was confirmed as the most suitable for the frozen and all lyophilised FMT forms.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Gut microbiota and health · Clostridium difficile and Clostridium perfringens research · Probiotics and Fermented Foods
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Kosice, 041 81 Kosice, Slovakia
2nd Department of Internal Medicine, Faculty of Medicine, Pavol Jozef Safarik University and Louis Pasteur University Hospital in Kosice, 040 11 Kosice, Slovakia
Department of Animal Physiology, Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Safarik University in Kosice, 040 01 Kosice, Slovakia
Center for Interdisciplinary Biosciences, Technology and Innovation Park, Pavol Jozef Safarik University in Kosice, 040 01 Kosice, Slovakia
Small Animal Clinic, University Veterinary Hospital, University of Veterinary Medicine and Pharmacy in Kosice, 041 81 Kosice, Slovakia
Center of Clinical and Preclinical Research—MEDIPARK, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, 040 11 Kosice, Slovakia
Funding
Slovak Research and Development Agency · VEGA
References (68)
Show source-provided references
1. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications10.1016/S0140-6736(19)31266-8 ↗
2. Therapies to modulate gut microbiota: Past, present and future10.3748/wjg.v26.i8.777 ↗
3. Fecal microbiota transplantation in disease therapy10.1016/j.cca.2019.12.010 ↗
4. Fecal microbiota transplantation in ulcerative colitis
5. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis10.1053/j.gastro.2015.03.045 ↗
6. Microbiota transplantation: Concept, methodology and strategy for its modernization10.1007/s13238-018-0541-8 ↗
7. Treatment of slow transit constipation with fecal microbiota transplantation10.1097/MCG.0000000000000472 ↗
8. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: A double-blind, randomised, placebo-controlled, parallel-group, single-centre trial10.1016/S2468-1253(17)30338-2 ↗
9. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial10.1002/hep.29306 ↗
10. Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft- versus -host-disease10.3324/haematol.2016.154351 ↗
11. Mo1667 Fecal microbiota transplantation for children with autism spectrum disorder10.1016/j.gie.2019.03.857 ↗
12. Overall rebalancing of gut microbiota is key to autism intervention10.3389/fpsyg.2022.862719 ↗
13. Fecal microbiota transplantation cured epilepsy in a case with Crohn’s disease: The first report10.3748/wjg.v23.i19.3565 ↗
14. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome10.1053/j.gastro.2012.06.031 ↗
15. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug10.1038/nm.4345 ↗
16. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease10.1016/j.cell.2016.11.018 ↗
17. Fecal microbiota transplantation: Current status and future directions10.1586/egh.11.71 ↗
18. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota10.1038/srep41802 ↗
19. Lauko, S., Gancarčíková, S., Hrčková, G., Hajdučková, V., Andrejčáková, Z., Fecskeová, L.K., Bertková, I., Hijová, E., Kamlárová, A., and Janíčko, M. (2023). Beneficial effect of faecal microbiota transplantation on mild, moderate and severe dextran sodium sulphate-induced ulcerative colitis in a pseudo germ-free animal model. Biomedicines, 12.10.3390/biomedicines12010043 ↗
20. FLASH: Fast length adjustment of short reads to improve genome assemblies10.1093/bioinformatics/btr507 ↗
21. QIIME allows analysis of high-throughput community sequencing data10.1038/nmeth.f.303 ↗
22. The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools10.1093/nar/gks1219 ↗
23. UCHIME improves sensitivity and speed of chimera detection10.1093/bioinformatics/btr381 ↗
24. UPARSE: Highly accurate OTU sequences from microbial amplicon reads10.1038/nmeth.2604 ↗
25. Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities10.1128/AEM.01541-09 ↗
26. MUSCLE: Multiple sequence alignment with high accuracy and high throughput10.1093/nar/gkh340 ↗
27. Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., and Zhang, C. (2019). Alteration of gut microbiota in inflammatory bowel disease (IBD): Cause or consequence? IBD treatment targeting the gut microbiome. Pathogens, 8.10.3390/pathogens8030126 ↗
28. Faecal microbial transplant
29. Navigating the microbiota seas: Triangulation finds a way forward10.1016/j.chom.2017.12.015 ↗
30. Gut microbiota in the pathogenesis of inflammatory bowel disease10.1007/s12328-017-0813-5 ↗
31. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn’s disease10.1159/000441768 ↗
32. Role of intestinal microbiota and metabolites in inflammatory bowel disease10.1097/CM9.0000000000000290 ↗
33. Association between Faecalibacterium prausnitzii reduction and inflammatory bowel disease: A meta-analysis and systematic review of the literature10.1155/2014/872725 ↗
34. Faecalibacterium prausnitzii produces butyrate to maintain th17/treg balance and to ameliorate colorectal colitis by inhibiting histone deacetylase 110.1093/ibd/izy182 ↗
35. Action and function of Faecalibacterium prausnitzii in health and disease10.1016/j.bpg.2017.09.011 ↗
36. Zuo, T., and Ng, S.C. (2018). The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front. Microbiol., 9.10.3389/fmicb.2018.02247 ↗
37. Mechanisms of inflammation-driven bacterial dysbiosis in the gut10.1038/mi.2016.75 ↗
38. The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease10.1016/j.coph.2020.08.009 ↗
39. Fecal microbiota transplantation results in bacterial strain displacement in patients with inflammatory bowel diseases10.1002/2211-5463.12744 ↗
40. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis10.1111/apt.14387 ↗
41. Bibbò, S., Settanni, C.R., Porcari, S., Bocchino, E., Ianiro, G., Cammarota, G., and Gasbarrini, A. (2020). Fecal microbiota transplantation: Screening and selection to choose the optimal donor. J. Clin. Med., 9.10.3390/jcm9061757 ↗
42. Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis10.1053/j.gastro.2018.12.001 ↗
43. Long-term safety of faecal microbiota transplantation for gastrointestinal diseases in China10.1016/S2468-1253(22)00170-4 ↗
44. Preservation by lyophilization of a human intestinal microbiota: Influence of the cultivation pH on the drying outcome and re-establishment ability10.1111/1751-7915.14007 ↗
45. Tian, H., Wang, X., Fang, Z., Li, L., Wu, C., Bi, D., Li, N., Chen, Q., and Qin, H. (2024). Fecal microbiota transplantation in clinical practice: Present controversies and future prospects. hLife, in press.10.1016/j.hlife.2024.01.006 ↗
46. Fouhy, F., Deane, J., Rea, M.C., O’Sullivan, Ó., Ross, R.P., O’Callaghan, G., Plant, B.J., and Stanton, C. (2015). The effects of freezing on faecal microbiota as determined using MiSeq sequencing and culture-based investigations. PLoS ONE, 10.10.1371/journal.pone.0119355 ↗
47. A guide for ex vivo handling and storage of stool samples intended for fecal microbiota transplantation10.1038/s41598-019-45173-4 ↗
48. Freeze-dried fecal samples are biologically active after long-lasting storage and suited to fecal microbiota transplantation in a preclinical murine model of Clostridioides difficile infection10.1080/19490976.2020.1759489 ↗
49. Optimisation of a propidium monoazide based method to determine the viability of microbes in faecal slurries for transplantation10.1016/j.mimet.2018.12.001 ↗
50. Bacterial viability in faecal transplants: Which bacteria survive10.1016/j.ebiom.2019.02.023 ↗
51. Stability and efficacy of frozen and lyophilized fecal microbiota transplant (FMT) product in a mouse model of Clostridium difficile infection (CDI)10.1016/j.anaerobe.2017.08.003 ↗
52. Chu, N.D., Smith, M.B., Perrotta, A.R., Kassam, Z., and Alm, E.J. (2017). Profiling living bacteria informs preparation of fecal microbiota transplantations. PLoS ONE, 12.10.1371/journal.pone.0170922 ↗
53. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: A randomized clinical trial10.1001/jama.2018.20046 ↗
54. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection10.1038/ajg.2011.482 ↗
55. Frozen faecal matter works as well as fresh for transplantation in C. difficile patients10.1136/bmj.i138 ↗
56. Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: A meta-analysis?10.1016/j.diagmicrobio.2017.05.007 ↗
57. Fang, H., Fu, L., and Wang, J. (2018). Protocol for fecal microbiota transplantation in inflammatory bowel disease: A systematic review and meta-analysis. Biomed. Res. Int., 2018.10.1155/2018/8941340 ↗
58. Anaerobic stool preparation method for fecal microbiota transplantation is not superior to conventional aerobic method in preserving anaerobic bacteria: P-12510.14309/00000434-201802001-00125 ↗
59. Mo1954 Anaerobic fecal microbiota transplantation preparations are not necessary for treatment successful engraftment microbial in recurrent C. difficile infection10.1016/S0016-5085(20)33151-6 ↗
60. Fecal filtrate transplantation protects against necrotizing enterocolitis10.1038/s41396-021-01107-5 ↗
61. SER109, an oral microbiome therapy for recurrent Clostridioides difficile infection10.1056/NEJMoa2106516 ↗
62. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection10.1053/j.gastro.2016.11.010 ↗
63. Mahdi, T., Desmons, A., Krasniqi, P., Lacorte, J.-M., Kapel, N., Lamazière, A., Fourati, S., and Eguether, T. (2024). Effect of stool sampling on a routine clinical method for the quantification of six short chain fatty acids in stool using gas chromatography–mass spectrometry. Microorganisms, 12.10.3390/microorganisms12040828 ↗
64. Ueyama, J., Oda, M., Hirayama, M., Sugitate, K., Sakui, N., Hamada, R., Ito, M., Saito, I., and Ohno, K. (2020). Freeze-drying enables homogeneous and stable sample preparation for determination of fecal short-chain fatty acids. Anal. Biochem., 589.10.1016/j.ab.2019.113508 ↗
65. A targeted metabolomic protocol for short-chain fatty acids and branched-chain amino acids10.1007/s11306-013-0500-6 ↗
66. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism10.1194/jlr.R036012 ↗
67. Randomised clinical trial: Faecal microbiota transplantation for recurrent clostridum difficile infection—Fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy10.1111/apt.13969 ↗
68. Jiang, Z.D., Jenq, R.R., Ajami, N.J., Petrosino, J.F., Alexander, A.A., Ke, S., Iqbal, T., DuPont, A.W., Muldrew, K., and Shi, Y. (2018). Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial. PLoS ONE, 13.10.1371/journal.pone.0205064 ↗